Article Text

Download PDFPDF

‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature?
  1. Marc Scherlinger1,2,3,
  2. Thierry Schaeverbeke1,2
  1. 1 Service de Rhumatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
  2. 2 Université de Bordeaux, Bordeaux, France
  3. 3 UMR-CNRS 5164 Immunoconcept, Bordeaux, France
  1. Correspondence to Dr Marc Scherlinger, Service de Rhumatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux 33076, France; marc.scherlinger{at}

Statistics from

We read with great interest the paper from Glintborg and coauthors ‘To switch or not to switch’ reporting biosimilar etanercept switching in Denmark.1

In the Danish Biologic (DANBIO) cohort, patient treated with originator etanercept (Enbrel) were informed of a mandatory switch to SB4. However, the 25 mg pen or a powder-based preparation of original etanercept (OE) were still available. At 1 year after this decision, the authors reported that only 79% of patients had switched to SB4 and 21% remained treated with the originator biologic.

In westernised countries, biologics therapies …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correspondence response
    Bente Glintborg Anne Gitte Loft Emina Omerovic Oliver Hendricks Asta Linauskas Jakob Espesen Kamilla Danebod Dorte Vendelbo Jensen Henrik Nordin Emil Barner Dalgaard Stavros Chrysidis Salome Kristensen Johnny Lillelund Raun Hanne Lindegaard Natalia Manilo Susanne Højmark Jakobsen Inger Marie Jensen Hansen Dorte Dalsgaard Pedersen Inge Juul Sørensen Lis Smedegaard Andersen Jolanta Grydehøj Frank Mehnert Niels Steen Krogh Merete Lund Hetland